657
Concern exists that preadmission warfarin use may be associated with an increased risk of intracerebral hemorrhage in patients with ischemic stroke receiving intravenous tissue plasminogen activator, even in those with an international normalized ratio <1.7.
 patients with ischemic stroke: Subject; increased risk of intracerebral hemorrhage: Effect; receiving intravenous tissue plasminogen activator: Treatment; preadmission warfarin: Treatment; ischemic stroke: Treatment.Disorder; warfarin: Treatment.Drug; intravenous tissue plasminogen activator: Treatment.Drug; warfarin: Combination.Drug; intravenous tissue plasminogen activator: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 patients with ischemic stroke: Subject; increased risk of intracerebral hemorrhage: Effect; receiving intravenous tissue plasminogen activator: Treatment; preadmission warfarin: Treatment; ischemic stroke: Treatment.Disorder; warfarin: Treatment.Drug; intravenous tissue plasminogen activator: Treatment.Drug; warfarin: Combination.Drug; intravenous tissue plasminogen activator: Combination.Drug